

Ira S Winer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/505664/publications.pdf>

Version: 2024-02-01

33
papers

1,661
citations

567281

15
h-index

434195

31
g-index

33
all docs

33
docs citations

33
times ranked

2215
citing authors

#	ARTICLE	IF	CITATIONS
1	Disparities in adjuvant treatment of high-grade endometrial cancer in the Medicare population. American Journal of Obstetrics and Gynecology, 2022, 226, 541.e1-541.e13.	1.3	12
2	Incidence and Survival of Multiple Primary Cancers in US Women With a Gynecologic Cancer. Frontiers in Oncology, 2022, 12, 842441.	2.8	2
3	Molecular profiles of endometrial cancer tumors among Black patients. Gynecologic Oncology, 2022, 166, 108-116.	1.4	11
4	Abstract CT180: Safety and efficacy of vibostolimab (vibo) plus pembrolizumab (pembro) and coformulation of vibo/pembro in ovarian cancer naive to PD-1/PD-L1 inhibitors. Cancer Research, 2022, 82, CT180-CT180.	0.9	0
5	The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer. Molecular Cancer Therapeutics, 2021, 20, 183-190.	4.1	6
6	Dual-Illumination Ultrasound/ Photoacoustic System for Cervical Cancer Imaging. IEEE Photonics Journal, 2021, 13, 1-10.	2.0	7
7	ONC201 induces the unfolded protein response (UPR) in high- and low- grade ovarian carcinoma cell lines and leads to cell death regardless of platinum sensitivity. Cancer Medicine, 2021, 10, 3373-3387.	2.8	6
8	Hysteroscopic Morcellation in Endometrial Cancer Diagnosis: Increased Risk?. Journal of Minimally Invasive Gynecology, 2021, 28, 1625-1632.	0.6	9
9	Prognostic value of changes in neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) for patients with cervical cancer undergoing definitive chemoradiotherapy (dCRT). Clinica Chimica Acta, 2020, 510, 711-716.	1.1	30
10	Tumor-associated macrophages derived from cancer stem cells. Acta Histochemica, 2020, 122, 151628.	1.8	18
11	Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncology, The, 2020, 21, 957-968.	10.7	140
12	Dual-Illumination Ultrasound/Photoacoustic Endoscopic System. , 2020, , .		4
13	Miniaturized phased-array ultrasound and photoacoustic endoscopic imaging system. Photoacoustics, 2019, 15, 100139.	7.8	34
14	Serum folate receptor β (sFR) in ovarian cancer diagnosis and surveillance. Cancer Medicine, 2019, 8, 920-927.	2.8	9
15	Involvement and comfort of gynecologic oncologists in the treatment of pediatric, adolescent, and young adult patients with gynecologic malignancies. International Journal of Gynecology and Obstetrics, 2017, 138, 177-182.	2.3	2
16	Recurrent Omental Hemangiopericytoma: A Therapeutic Challenge. Case Reports in Obstetrics and Gynecology, 2016, 2016, 1-4.	0.3	2
17	Tubal Ligation and Risk of Endometrial Cancer. International Journal of Gynecological Cancer, 2016, 26, 464-471.	2.5	7
18	Comparative Analysis of Differentially Expressed miRNAs and their Downstream mRNAs in Ovarian Cancer and its Associated Endometriosis. Journal of Cancer Science & Therapy, 2015, 07, 258-265.	1.7	28

#	ARTICLE	IF	CITATIONS
19	Primary debulking surgery and neoadjuvant chemotherapy in the treatment of advanced epithelial ovarian carcinoma. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 5-10.	5.9	12
20	The prognostic significance of histologic type in early stage cervical cancer – A multi-institutional study. <i>Gynecologic Oncology</i> , 2015, 137, 474-478.	1.4	41
21	Significance of Lymphovascular Space Invasion in Uterine Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 47-56.	1.4	29
22	Management of squamous cell vulvar cancer: A review. <i>Journal of Obstetrics and Gynaecology Research</i> , 2014, 40, 1217-1225.	1.3	29
23	Chemotherapy of vulvar cancer: a review. <i>Wiener Klinische Wochenschrift</i> , 2013, 125, 119-128.	1.9	15
24	Vulvar/Vaginal Melanoma. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1118-1126.	2.5	53
25	Clinical and Pathologic Characteristics of Serous Carcinoma Confined to the Endometrium. <i>International Journal of Gynecological Pathology</i> , 2013, 32, 181-187.	1.4	30
26	Merkel cell carcinoma in a patient with noninvasive vulvar Paget's disease. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 207, e9-e11.	1.3	7
27	A case of progressive mucinous ovarian cancer of low malignant potential responsive to biologic therapy with Bevacizumab. <i>Gynecologic Oncology</i> , 2010, 116, 578-579.	1.4	5
28	Bevacizumab for the Treatment of Non-Resectable Pseudomyxoma peritonei Associated with Mucinous Ovarian Tumor of Low Malignant Potential – A Comparison of Two Cases. <i>Case Reports in Oncology</i> , 2010, 3, 1-8.	0.7	7
29	F3-Targeted Cisplatin-Hydrogel Nanoparticles as an Effective Therapeutic That Targets Both Murine and Human Ovarian Tumor Endothelial Cells <i>In vivo</i> . <i>Cancer Research</i> , 2010, 70, 8674-8683.	0.9	90
30	Drosophila split ends Homologue SHARP Functions as a Positive Regulator of Wnt/ β -Catenin/T-Cell Factor Signaling in Neoplastic Transformation. <i>Cancer Research</i> , 2007, 67, 482-491.	0.9	32
31	Lysine Residues Lys-19 and Lys-49 of β -Catenin Regulate Its Levels and Function in T Cell Factor Transcriptional Activation and Neoplastic Transformation. <i>Journal of Biological Chemistry</i> , 2006, 281, 26181-26187.	3.4	47
32	ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with β -catenin defects and promotes neoplastic transformation. <i>Cancer Cell</i> , 2002, 1, 145-155.	16.8	148
33	Effective expression of small interfering RNA in human cells. <i>Nature Biotechnology</i> , 2002, 20, 505-508.	17.5	789